Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

The trifunctional antibody catumaxomab is a targeted immunotherapy for the intraperitoneal treatment of malignant ascites. In a Phase II/III trial in cancer patients (n = 258) with malignant ascites, catumaxomab showed a clear clinical benefit vs. paracentesis and had an acceptable safety profile. H...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2012-05, Vol.130 (9), p.2195-2203
Hauptverfasser:	Ott, Marion G., Marmé, Frederik, Moldenhauer, Gerhard, Lindhofer, Horst, Hennig, Michael, Spannagl, Rolf, Essing, Mirko M., Linke, Rolf, Seimetz, Diane
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies, Anti-Idiotypic - blood Antibodies, Bispecific - administration & dosage Antibodies, Bispecific - immunology Antibodies, Monoclonal - therapeutic use Ascites - blood Ascites - drug therapy Ascites - immunology Biological and medical sciences Biomarkers, Pharmacological - blood Cancer Cancer Therapy catumaxomab clinical outcome Clinical outcomes Female Humans humoral response Immunity, Humoral - immunology Immunotherapy - methods malignant ascites Medical research Medical sciences Mice Ovarian Neoplasms - blood Ovarian Neoplasms - drug therapy Ovarian Neoplasms - immunology Ovarian Neoplasms - pathology Paracentesis - methods Peritoneal Neoplasms - blood Peritoneal Neoplasms - drug therapy Peritoneal Neoplasms - immunology Peritoneal Neoplasms - pathology Rats Stomach Neoplasms - blood Stomach Neoplasms - drug therapy Stomach Neoplasms - immunology Stomach Neoplasms - pathology Survival Analysis Treatment Outcome trifunctional antibody Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!